CXCL9 and melanoma: While this discrepancy may be imputable to heterogeneity between studies, on-treatment changes involving soluble immune mediators (including CXCL9 transcriptional changes) associated with response to ICI in patients with advanced melanoma have been mainly reported within the tumour microenvironment by previous studies.36